Literature DB >> 31546266

From the Origins of Pharmacogenetics to First Applications in Psychiatry.

Daniel J Müller1,2,3, Zoe Rizhanovsky1.   

Abstract

Pharmacogenetics is the division of science addressing how genetic factors contribute to the metabolism, response, and side effects of a given medication. What was once regarded as a subdivision of genetics and pharmacology is now recognized as its own field and has its own unique story of origin. While the term "pharmacogenetics" was coined by Friedrich Vogel in 1959, the relevance of inherited genetic traits in affecting the clinical outcome to xenobiotics has been observed long before. In fact, there is much hope that pharmacogenetics can help unravel the "mysteries" as to why different people may display variable responses to the same medication as well as identify new drug targets. This article will highlight the conceptual framework for pharmacogenetics advanced by pioneer scientists Arno Motulsky and Friedrich Vogel (both human geneticists), as well as Werner Kalow (clinical pharmacologist), leading up to the creation of modern pharmacogenetics. Finally, the practical implications and first steps toward implementation for current psychiatric treatment are reviewed followed by an outlook on future studies. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2019        PMID: 31546266     DOI: 10.1055/a-0979-2322

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  2 in total

Review 1.  Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application.

Authors:  Lara E Murphy; Trehani M Fonseka; Chad A Bousman; Daniel J Müller
Journal:  Mol Psychiatry       Date:  2021-11-09       Impact factor: 15.992

2.  GABAergic polygenic risk for cocaine use disorder is negatively correlated with precuneus activity during cognitive control in African American individuals.

Authors:  Bao-Zhu Yang; Iris M Balodis; Hedy Kober; Patrick D Worhunsky; Cheryl M Lacadie; Joel Gelernter; Marc N Potenza
Journal:  Addict Behav       Date:  2020-10-10       Impact factor: 3.913

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.